Koers Biofrontera AG OTC Markets
Aandelen
BFRA
US09075G1058
Farmaceutische producten
Omzet 2021 | 28,79 mln. 31 mln. | Omzet 2022 | 25,74 mln. 27,72 mln. | Marktkapitalisatie | 97,31 mln. 105 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | 38 mln. 40,92 mln. | Nettowinst (verlies) 2022 | -44 mln. -47,39 mln. | EV/omzet 2021 | 2,79 x |
Nettoliquiditeiten 2021 | 3,61 mln. 3,89 mln. | Nettoliquiditeiten 2022 | 4,88 mln. 5,25 mln. | EV/omzet 2022 | 3,59 x |
K/w-verhouding 2021 |
2,18
x | K/w-verhouding 2022 |
-1,98
x | Werknemers | 92 |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 32,4% |
Recentste transcriptie over Biofrontera AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Director of Finance/CFO | 55 | 12-09-22 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 63 | 14-12-21 | |
Director/Board Member | - | 14-12-21 | |
Heikki Lanckriet
BRD | Director/Board Member | 46 | 14-12-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,38% | 684 mld. | |
+26,51% | 568 mld. | |
-4,36% | 361 mld. | |
+19,30% | 329 mld. | |
+3,73% | 284 mld. | |
+16,70% | 240 mld. | |
+8,78% | 208 mld. | |
-7,93% | 200 mld. | |
+7,68% | 166 mld. |